Literature DB >> 29518400

Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation.

Guo-Fu Li1, Guo Yu2, Yanfei Li3, Yi Zheng4, Qing-Shan Zheng5, Hartmut Derendorf6.   

Abstract

Quantitative prediction of unbound drug fraction (fu) is essential for scaling pharmacokinetics through physiologically based approaches. However, few attempts have been made to evaluate the projection of fu values under pathological conditions. The primary objective of this study was to predict fu values (n = 105) of 56 compounds with or without the information of predominant binding protein in patients with varying degrees of hepatic insufficiency by accounting for quantitative changes in molar concentrations of either the major binding protein or albumin plus alpha 1-acid glycoprotein associated with differing levels of hepatic dysfunction. For the purpose of scaling, data pertaining to albumin and α1-acid glycoprotein levels in response to differing degrees of hepatic impairment were systematically collected from 919 adult donors. The results of the present study demonstrate for the first time the feasibility of physiologically based scaling fu in hepatic dysfunction after verifying with experimentally measured data of a wide variety of compounds from individuals with varying degrees of hepatic insufficiency. Furthermore, the high level of predictive accuracy indicates that the inter-relation between the severity of hepatic impairment and these plasma protein levels are physiologically accurate. The present study enhances the confidence in predicting fu in hepatic insufficiency, particularly for albumin-bound drugs.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  albumin; alpha 1-acid glycoprotein; clinical pharmacokinetics; fraction unbound; hepatic impairment; physiologically based pharmacokinetics; plasma protein binding

Mesh:

Substances:

Year:  2018        PMID: 29518400     DOI: 10.1016/j.xphs.2018.02.021

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese.

Authors:  Guo Yu; Hong-Hao Zhou; Qing-Shan Zheng; Guo-Fu Li
Journal:  Eur J Clin Pharmacol       Date:  2018-12-19       Impact factor: 2.953

2.  Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.

Authors:  Guo-Fu Li; Qing-Shan Zheng; Yichao Yu; Wei Zhong; Hong-Hao Zhou; Furong Qiu; Guangji Wang; Guo Yu; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

3.  Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective.

Authors:  Guo Yu; Guo-Fu Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

4.  Evaluation of Quantitative Structure Property Relationship Algorithms for Predicting Plasma Protein Binding in Humans.

Authors:  Yejin Esther Yun; Rogelio Tornero-Velez; S Thomas Purucker; Daniel T Chang; Andrea N Edginton
Journal:  Comput Toxicol       Date:  2021-02-01

Review 5.  Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.

Authors:  Pieter-Jan De Sutter; Maxime Van Haeverbeke; Eva Van Braeckel; Stephanie Van Biervliet; Jan Van Bocxlaer; An Vermeulen; Elke Gasthuys
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-29

Review 6.  The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development.

Authors:  Zhengying Zhou; Jinwei Zhu; Muhan Jiang; Lan Sang; Kun Hao; Hua He
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.